These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22356552)

  • 1. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
    Norman P
    Expert Opin Ther Pat; 2012 Mar; 22(3):335-9. PubMed ID: 22356552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
    Riccaboni M; Bianchi I; Petrillo P
    Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
    Thorarensen A; Kaila N
    Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.
    Norman P
    Expert Opin Ther Pat; 2009 Oct; 19(10):1469-72. PubMed ID: 19552507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2010 patent landscape for spleen tyrosine kinase inhibitors.
    Moretto AF; Dehnhardt C; Kaila N; Papaioannou N; Thorarensen A
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):97-120. PubMed ID: 22292554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
    Singh R; Masuda ES; Payan DG
    J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213
    [No Abstract]   [Full Text] [Related]  

  • 10. Highly potent aminopyridines as Syk kinase inhibitors.
    Castillo M; Forns P; Erra M; Mir M; López M; Maldonado M; Orellana A; Carreño C; Ramis I; Miralpeix M; Vidal B
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5419-23. PubMed ID: 22877633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and SAR of novel Naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK).
    Cywin CL; Zhao BP; McNeil DW; Hrapchak M; Prokopowicz AS; Goldberg DR; Morwick TM; Gao A; Jakes S; Kashem M; Magolda RL; Soll RM; Player MR; Bobko MA; Rinker J; DesJarlais RL; Winters MP
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1415-8. PubMed ID: 12668002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respivert's multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449.
    Norman P
    Expert Opin Ther Pat; 2014 Dec; 24(12):1397-407. PubMed ID: 25407284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the role of water molecules for docking and receptor guided 3D-QSAR analysis of naphthyridine derivatives as spleen tyrosine kinase (Syk) inhibitors.
    Kaur M; Bahia MS; Silakari O
    J Chem Inf Model; 2012 Oct; 52(10):2619-30. PubMed ID: 22900966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
    Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syk kinase as a treatment target for therapy in autoimmune diseases.
    Kyttaris VC; Tsokos GC
    Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
    Uckun FM; Qazi S
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
    Zhao H; Caflisch A
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syk inhibitors with high potency in presence of blood.
    Thoma G; Blanz J; Bühlmayer P; Drückes P; Kittelmann M; Smith AB; van Eis M; Vangrevelinghe E; Zerwes HG; Che JJ; He X; Jin Y; Lee CC; Michellys PY; Uno T; Liu H
    Bioorg Med Chem Lett; 2014 May; 24(10):2278-82. PubMed ID: 24726806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.